Please login to the form below

Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

Eliquis (apixaban), which rocketed 47% to $889m.

Pfizer’s flat sales focus investor attention on M&A

Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar
Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
BMS’ Opdivo defies naysayers with healthy growth

Outside oncology, BMS’top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s ... This year saw a reversal of fortune however, with
Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

On the plus side, the firm reported solid growth for other newer products such as breast cancer drug Ibrance (palbociclib) and oral anticoagulant Eliquis (apixaban), up 66% to $853m and 50%

More from news
Approximately 19 fully matching, plus 82 partially matching documents found.

The good, the bad and the ugly

This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Modern anticoagulants threaten status quo

Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PPD expands global product department with new therapeutic area heads

Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Add my company

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....